Clinical trial NCT03535168: Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients
Official title: Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Subjects to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1902607 Including Its Effect on the Pharmacokinetics of a Sub-therapeutic Dose of Midazolam (MDZ), Followed by (Part 2) a Two-way Crossover Administration of Four Different Doses of BAY1902607 in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of Concept
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Cough
Keywords: Healthy volunteers
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2018-05-24
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Part 1: Sequential parallel-group Part 2: Two-arm crossover
Primary purpose: TREATMENT

Brief summary: The primary objectives of this study:

* To investigate the safety and tolerability of ascending repeated oral doses of BAY1902607 in healthy subjects (Part 1).
* To investigate the effect of BAY1902607 on the pharmacokinetics (PK) of a sub-therapeutic 1 mg dose of midazolam (Part 1).
* To investigate the safety, tolerability and efficacy of BAY1902607 in patients with refractory chronic cough (Part 2).


Eligibility criteria: Inclusion Criteria:

Part 1:

* Male; healthy according to complete medical history, including the physical examination, vital signs (blood pressure, heart rate), 12-lead ECG, clinical laboratory tests
* Age: 18-45 years (inclusive) at the first screening visit
* Non-smoker for at least 6 months and with a pack year history of equal to or less than 5 years
* Subjects, who are sexually active and have not been surgically sterilized, must agree to use two reliable and acceptable methods of contraception simultaneously, when having sexual intercourse with women of childbearing potential (one method used by the subject, one method used by the partner) during the study and for 90 days after receiving the investigational medicinal product, and not to act as sperm donor for 90 days after dosing. \[Acceptable methods of contraception include for example: (a) condoms (male or female) with or without a spermicidal agent, (b) diaphragm or cervical cap with spermicide, (c) intrauterine device, (d) hormone-based contraception\]

Part 2:

* Age: ≥18 years at the first screening visit
* Refractory chronic cough for at least one year that has been shown to be unresponsive to treatment of cough according to the 2006 British Thoracic Society (BTS) guideline
* Score of ≥ 40 mm on the Cough Severity visual analogue scale (VAS) at screening
* For female patients:

Confirmed post-menopausal woman (defined as exhibiting spontaneous amenorrhea for at least 12 months before screening or as exhibiting spontaneous amenorrhea for 6 months before screening with documented serum follicle-stimulating hormone (FSH) levels \> 40 mIU/mL) or Woman without childbearing potential based on surgical treatment at least 6 weeks before screening, such as bilateral tubal ligation, bilateral oophorectomy with or without hysterectomy (documented by medical report verification) or Woman of childbearing potential that agrees to use two reliable and acceptable methods of contraception simultaneously (one method used by the study patient and one method used by the partner) during the study and for at least 31 days (1 average menstrual cycle of 28 days plus approx. 5 half-lives of BAY 1902607) after the last dose. In addition during the study and for at least 31 days after the last dose women of child bearing potential are not allowed to donate oocytes.

Exclusion Criteria:

Part 1:

* Relevant diseases potentially interfering with the study objectives (e.g. respiratory diseases) within the four weeks before screening or between screening and randomization
* Any febrile illness within the four weeks before screening or between screening and randomization
* Medical history of hypogeusia/dysgeusia or the subject has a dysfunction in his ability to taste, as revealed by the taste-disturbance questionnaire during screening and the predose procedures

Part 2:

* FEV1(Forced Expiratory Volume in 1 second) or FVC(Forced Vital Capacity ) of less than 60% of predicted normal, at screening
* History of upper or lower respiratory tract infection or recent significant change in pulmonary status within the 4 weeks before screening
* Current smoking habit or history of smoking within the 6 months before the screening visit
* History of smoking (at any time) for more than 20 pack-years in total (20 cigarettes per pack)

Primary outcomes:
measure: Number of subjects with Treatment-Emergent Adverse Events (TEAEs) by Severity in Part 1
timeFrame: Approximately 5 weeks
measure: Number of subjects with Treatment-Emergent Adverse Events (TEAEs) by Severity in Part 2
timeFrame: Approximately 12 weeks
measure: AUC of midazolam without BAY1902607
timeFrame: At Day -1
measure: AUC of midazolam in combination with BAY1902607
timeFrame: At Day 13
measure: Cmax of midazolam in combination with BAY1902607
timeFrame: At Day 13
measure: Cmax of midazolam without BAY1902607
timeFrame: At Day -1
measure: Number of Coughs Experienced by the Patient Within a 24-hour Period (24- hour cough count/hour) in Part 2
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Eindhoven
country: Netherlands
facility: Catharina Ziekenhuis
state: Noord-Brabant
city: Zwolle
country: Netherlands
facility: Isala
city: Belfast
country: United Kingdom
facility: Queen's University
state: Antrim
city: Birmingham
country: United Kingdom
facility: Birmingham Heartlands Hospital
state: West Midlands
city: Cottingham
country: United Kingdom
facility: Castle Hill Hospital
city: London
country: United Kingdom
facility: King's College Hospital - NHS Foundation Trust
city: Manchester
country: United Kingdom
facility: Medicines Evaluation Unit
city: Manchester
country: United Kingdom
facility: University Hospital of South Manchester
Study officials:
References: